Mylan Loses Duragesic Case; Generic Launch Timing Dispute Moves To FDA

The launch timing for the first generic version of Johnson & Johnson/Alza's Duragesic fentanyl patch will depend on FDA's decision about a six-month pediatric exclusivity extension for the product